Skip to main
SGEN
SGEN logo

Seagen (SGEN) Stock Forecast & Price Target

Seagen (SGEN) Analyst Ratings

Based on 30 analyst ratings
Buy
Strong Buy 30%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 3%

Bulls say

Seagen is a well-established company with marketable therapies for a variety of cancers, combined with a strong licensing program for its antibody-drug conjugate technology. Its lead product Adcetris has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma, while its newly approved product Padcev, when combined with Keytruda, nearly doubled the PFS & OS seen with a chemotherapeutic approach. EV-302 data from the Phase 3KEYNOTE-A39/EV-302 study was also promising, providing grounds for acceleration approval in April of 2023. This, combined with Seagen's strong financials and key data metrics, make the company an attractive investment for the long term.

Bears say

Seagen is generating strong revenue from its products, but has limited pipeline upside to drive sustained long-term growth. Research and Development spending has significantly increased in recent quarters, while profits remain marginal. Cash flow has decreased in the past few years, indicating that the current level of growth may not be sustainable. As a result, Seagen's valuation is likely to remain under pressure in the near-term.

Seagen (SGEN) has been analyzed by 30 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seagen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seagen (SGEN) Forecast

Analysts have given Seagen (SGEN) a Buy based on their latest research and market trends.

According to 30 analysts, Seagen (SGEN) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $156.97, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $156.97, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seagen (SGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.